NEW YORK (GenomeWeb) – Nuclea Biotechnologies Founder and former CEO Patrick Muraca is attempting to buy the bankrupt company's assets for $330,000 after they failed to sell at auction in January.

Don Beskrone, Nuclea's Chapter 7 trustee, filed a motion in US Bankruptcy Court for the District of Delaware on March 6 requesting that the court approve the sale of Nuclea's assets to NanoMolecularDx (NMDX), the company Muraca founded as a spinoff from Nuclea in 2015 upon being replaced as Nuclea's President and CEO by Donald Pogorzelski, a former president of Genzyme Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.